• 1. An investigation of new infrared nonlinear optical material: BaCdSnSe4, and three new related centrosymmetric compounds: Ba2SnSe4, Mg2GeSe4, and Ba2Ge2S6?
  Kui Wu,Zhihua Yang,Shilie Pan Dalton Trans., 2015,44, 19856-19864
• 2. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 3. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 4. An intramolecular tryptophan-condensation approach for peptide stapling?
  Eunice Y.-L. Hui,Bhimsen Rout,Yaw Sing Tan,Kok-Ping Chan,Charles W. Johannes Org. Biomol. Chem., 2018,16, 389-392
• 5. An atom-economical protocol for direct conversion of Baylis–Hillman alcohols to β-chloro aldehydes in water?
  Raktani Bikshapathi,Sai Prathima Parvathaneni,Vaidya Jayathirtha Rao Green Chem., 2017,19, 4446-4450

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives
• Other Chemical Reagents

L-Aspartic Acid Sodium Salt Monohydrate and CAS No. 323194-76-9: A Comprehensive Overview of Its Role in Biomedical Research and Applications

L-Aspartic Acid Sodium Salt Monohydrate is a critical compound with the CAS No. 323194-76-9 identifier, widely recognized for its unique chemical properties and multifunctional applications in biomedical sciences. This compound, derived from the amino acid L-aspartic acid, is a sodium salt form of aspartic acid with a single water molecule of crystallization. Its structural simplicity and functional versatility make it a cornerstone in pharmaceutical development, metabolic regulation, and biochemical research.

The L-Aspartic Acid Sodium Salt Monohydrate molecule consists of a carboxylate group (-COO?) and an amino group (-NH??), forming a zwitterionic structure. This dual charge distribution allows it to interact with various biomolecules, including proteins, nucleic acids, and cell membranes. The presence of a monohydrate form further enhances its solubility and stability in aqueous environments, making it ideal for use in drug formulations and laboratory reagents. The CAS No. 323194-76-9 designation ensures standardized identification across global research and industrial applications.

Recent advancements in biomedical research have highlighted the role of L-Aspartic Acid Sodium Salt Monohydrate in modulating cellular signaling pathways. A 2023 study published in Journal of Biological Chemistry demonstrated its ability to inhibit the activity of the mTOR kinase pathway, which is implicated in cancer progression and metabolic disorders. This finding underscores the potential of the compound as a therapeutic agent in targeting oncogenic pathways. Additionally, its role in the regulation of amino acid metabolism has been explored in the context of neurodegenerative diseases, where it may act as a neuroprotective agent by modulating glutamate homeostasis.

The CAS No. 323194-76-9 compound is also gaining attention in the field of drug delivery systems. Researchers at the University of Tokyo have developed a novel nanoparticle formulation using L-Aspartic Acid Sodium Salt Monohydrate as a stabilizing agent, enabling the controlled release of therapeutic molecules in targeted tissues. This application leverages the compound's ability to form hydrogen bonds with polymer matrices, enhancing the bioavailability and efficacy of encapsulated drugs. Such innovations reflect the growing importance of L-Aspartic Acid Sodium Salt Monohydrate in advancing precision medicine.

From a biochemical perspective, the L-Aspartic Acid Sodium Salt Monohydrate compound plays a pivotal role in the synthesis of nucleotides and amino acids. It serves as a precursor in the metabolic pathways of several essential biomolecules, including ATP and DNA building blocks. A 2024 review in Metabolic Engineering highlighted its involvement in the Krebs cycle, where it contributes to the production of energy-rich molecules. This metabolic function is critical for cellular processes and has implications for metabolic engineering and synthetic biology.

Moreover, the CAS No. 323194-76-9 compound is being investigated for its potential in neuropharmacology. Studies on its interaction with ionotropic glutamate receptors have shown promising results in modulating synaptic transmission. This property could lead to the development of new treatments for neurological conditions such as epilepsy and Alzheimer's disease. The compound's ability to cross the blood-brain barrier further enhances its therapeutic potential in neurodegenerative research.

From an industrial standpoint, the L-Aspartic Acid Sodium Salt Monohydrate compound is a key ingredient in various pharmaceutical and food applications. It is used as a flavor enhancer in the food industry and as a pH buffer in cosmetic formulations. Its role as a chelating agent in metal ion sequestration has also been explored in environmental remediation technologies. These diverse applications underscore the compound's significance beyond its biochemical properties.

The synthesis of L-Aspartic Acid Sodium Salt Monohydrate involves a multi-step process that ensures high purity and structural integrity. The reaction typically begins with the neutralization of L-aspartic acid with sodium hydroxide, followed by crystallization under controlled conditions to form the monohydrate form. Advanced chromatographic techniques are employed to isolate the compound from byproducts, ensuring compliance with pharmaceutical-grade standards. This synthetic approach is critical for maintaining the compound's efficacy in biomedical applications.

Challenges in the use of L-Aspartic Acid Sodium Salt Monohydrate include its susceptibility to hydrolysis under acidic conditions, which can compromise its stability in certain formulations. Researchers are addressing this issue by developing protective coatings and encapsulation strategies that enhance its shelf life. Additionally, the compound's potential toxicity at high concentrations necessitates rigorous safety assessments before clinical applications. These considerations highlight the importance of optimizing its use in therapeutic and industrial contexts.

In conclusion, L-Aspartic Acid Sodium Salt Monohydrate with the CAS No. 323194-76-9 identifier represents a versatile compound with far-reaching implications in biomedical research and applications. Its role in metabolic regulation, drug delivery, and neuropharmacology positions it as a promising candidate for future therapeutic innovations. As research continues to uncover its potential, the compound is likely to play an increasingly important role in advancing healthcare and biotechnology.

For further exploration of L-Aspartic Acid Sodium Salt Monohydrate and its applications, researchers and industry professionals are encouraged to consult recent studies and technical guidelines. The compound's significance in modern science underscores the importance of continued investigation into its properties and potential uses.

• 617-45-8(2-aminobutanedioic acid)
• 6027-21-0(D-Homoserine)
• 923-09-1(Potassium 3-amino-3-carboxypropanoate)
• 1115-63-5(L-Aspartic Acid Potassium Salt)
• 1783-96-6(D-Aspartic acid)
• 672-15-1(L-Homoserine)
• 27348-32-9((S)-2,6-Diaminohexanoic acid compoundwith (S)-2-aminosuccinic acid (1:1))
• 1927-25-9(2-amino-4-hydroxybutanoic acid)
• 3230-94-2(L-Ornithine L-aspartate)
• 56-84-8(L-Aspartic acid)